All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What targeted therapies are showing promise for the treatment of patients with pediatric lymphoma?

During the 2021 American Society of Pediatric Hematology/Oncology (ASPHO) Conference, the Lymphoma Hub spoke with Peter Cole, Rutgers Cancer Institute of New Jersey, New Brunswick, US. We asked, What targeted therapies are showing promise for the treatment of patients with pediatric lymphoma?

What targeted therapies are showing promise for the treatment of patients with pediatric lymphoma?

Cole firstly summarizes trial data for brentuximab vedotin, a CD30-targeting antibody–drug conjugate, and it's potential to replace chemotherapy as frontline treatment. He then describes the CheckMate-744 trial, investigating a combination of nivolumab, a checkpoint inhibitor, with brentuximab vedotin in children with relapsed/refractory Hodgkin lymphoma. He finishes by outlining future trials for these novel agents.

Share: